Post-exposure prophylaxis for HIV: Difference between revisions
From IDWiki
m (Aidan moved page RNA Human immunodeficiency virus HIV PEP to HIV post-exposure prophylaxis without leaving a redirect) |
mNo edit summary |
||
| Line 1: | Line 1: | ||
| ⚫ | |||
= HIV post-exposure prophylaxis (PEP) = |
|||
| ⚫ | |||
* Can be sexual or non-sexual; consensual or non-consensual; and heterosexual or homosexual |
* Can be sexual or non-sexual; consensual or non-consensual; and heterosexual or homosexual |
||
= Risk Assessment = |
|||
{| |
{| |
||
| Line 57: | Line 55: | ||
|} |
|} |
||
= Investigations = |
|||
* HIV testing at baseline and 12 weeks |
* HIV testing at baseline and 12 weeks |
||
| Line 68: | Line 66: | ||
* Pregnancy test at baseline |
* Pregnancy test at baseline |
||
= Treatment = |
|||
* Screen for sexual assault, counsel about safe sex |
* Screen for sexual assault, counsel about safe sex |
||
| Line 77: | Line 75: | ||
* Don't forget above screening |
* Don't forget above screening |
||
= Follow-up = |
|||
* Initial visit; follow-up at 4-6 weeks; then repeat bloodwork at 4 months |
* Initial visit; follow-up at 4-6 weeks; then repeat bloodwork at 4 months |
||
* Take advantage of the opportunity to counsel patients on STIs, substance use, etc. |
* Take advantage of the opportunity to counsel patients on STIs, substance use, etc. |
||
= Further Reading = |
|||
* Tan ''et al''. [https://doi.org/10.1503/cmaj.170494 Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis]. ''CMAJ'' 2017;189(47):e1448-e1458. |
* Tan ''et al''. [https://doi.org/10.1503/cmaj.170494 Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis]. ''CMAJ'' 2017;189(47):e1448-e1458. |
||
[[Category:HIV]] |
|||
Revision as of 23:42, 14 August 2019
Exposures
- Can be sexual or non-sexual; consensual or non-consensual; and heterosexual or homosexual
Risk Assessment
| Level | Exposure | Estimated risk per act % |
|---|---|---|
| Very high | Transfusion | 92.5 |
| High | Anal (receptive) | 1.38 |
| Needle sharing | 0.63 | |
| Moderate | Anal (insertive) | 0.11 |
| Vaginal (receptive) | 0.08 | |
| Vaginal (insertive) | 0.04 | |
| Low | Oral sex (giving) | — |
| Oral sex (receiving) | — | |
| Oral-anal contact | — | |
| Sharing sex toys | — | |
| Blood on compromised skin | — |
Investigations
- HIV testing at baseline and 12 weeks
- HAV-Ab, HBsAg/sAb/cAb at baseline
- HCV-Ab at baseline and 12 weeks
- Gonorrhea and chlamydia of urine, throat, and rectum at baseline and 12 weeks
- Sypthilis at baseline and 12 weeks
- CBC at baseline
- ALT and creatinine at baseline, repeated at 2 weeks if abnormal
- Pregnancy test at baseline
Treatment
- Screen for sexual assault, counsel about safe sex
- Start treatment within 72 hours
- Tenofovir/emtricitabine 300/200 with raltegravir 400 BID, for 28 days
- Preferred alternatives include TDF/FTC with darunavir/ritonavir or dolutegravir
- Other alternatives include many
- Don't forget above screening
Follow-up
- Initial visit; follow-up at 4-6 weeks; then repeat bloodwork at 4 months
- Take advantage of the opportunity to counsel patients on STIs, substance use, etc.
Further Reading
- Tan et al. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ 2017;189(47):e1448-e1458.
